Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2022

Primary Completion Date

September 4, 2022

Study Completion Date

October 27, 2022

Conditions

Healthy

Interventions

DRUG

Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)

2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg

DRUG

Nirmatrelvir 150 mg + Ritonavir 100 mg (test)

2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg

DRUG

Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)

2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg

Trial Locations (1)

Genuine Research Center GRC, Cairo